AU2019337564A1 - Methods for treating pancreatitis - Google Patents

Methods for treating pancreatitis Download PDF

Info

Publication number
AU2019337564A1
AU2019337564A1 AU2019337564A AU2019337564A AU2019337564A1 AU 2019337564 A1 AU2019337564 A1 AU 2019337564A1 AU 2019337564 A AU2019337564 A AU 2019337564A AU 2019337564 A AU2019337564 A AU 2019337564A AU 2019337564 A1 AU2019337564 A1 AU 2019337564A1
Authority
AU
Australia
Prior art keywords
antibody
pancreatitis
functional fragment
seq
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019337564A
Other languages
English (en)
Inventor
Dannielle D. ENGLE
David A. Tuveson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of AU2019337564A1 publication Critical patent/AU2019337564A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2019337564A 2018-09-10 2019-09-09 Methods for treating pancreatitis Pending AU2019337564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
US62/729,354 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Publications (1)

Publication Number Publication Date
AU2019337564A1 true AU2019337564A1 (en) 2021-05-06

Family

ID=69776851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019337564A Pending AU2019337564A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Country Status (13)

Country Link
US (1) US12378320B2 (https=)
EP (1) EP3849605A4 (https=)
JP (1) JP7560445B2 (https=)
KR (1) KR20210073515A (https=)
CN (2) CN120267815A (https=)
AU (1) AU2019337564A1 (https=)
BR (1) BR112021004444A2 (https=)
CA (1) CA3112382A1 (https=)
CL (2) CL2021000585A1 (https=)
IL (1) IL281343A (https=)
MX (1) MX2021002761A (https=)
SG (1) SG11202102416SA (https=)
WO (1) WO2020055768A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102416SA (en) 2018-09-10 2021-04-29 Cold Spring Harbor Laboratory Methods for treating pancreatitis
US20250297027A1 (en) * 2021-01-12 2025-09-25 Yeda Research And Development Co. Ltd. Antibodies to cancer glycosylation and uses thereof
JP2024511189A (ja) * 2021-03-26 2024-03-12 ビオンテック・ソシエタス・エウロパエア がんの処置における抗ｃａ１９－９抗体およびｆｏｌｆｉｒｉｎｏｘを用いた組合せ療法。
US20250302409A1 (en) * 2024-03-26 2025-10-02 Hepatiq, Inc. Determining pancreas disease using functional imaging

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
HUE026444T2 (en) 2005-08-05 2016-05-30 Araim Pharmaceuticals Inc Tissue protection peptides and their use
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP5919604B2 (ja) 2008-08-08 2016-05-18 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗膵癌抗体
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
HK1223298A1 (zh) 2013-07-17 2017-07-28 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
KR102313341B1 (ko) * 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
SG11202102416SA (en) 2018-09-10 2021-04-29 Cold Spring Harbor Laboratory Methods for treating pancreatitis

Also Published As

Publication number Publication date
EP3849605A4 (en) 2022-06-15
KR20210073515A (ko) 2021-06-18
CN113056286A (zh) 2021-06-29
EP3849605A1 (en) 2021-07-21
CL2022000091A1 (es) 2022-11-18
CL2021000585A1 (es) 2021-08-13
IL281343A (en) 2021-04-29
US20220049011A1 (en) 2022-02-17
CA3112382A1 (en) 2020-03-19
SG11202102416SA (en) 2021-04-29
BR112021004444A2 (pt) 2021-06-01
US12378320B2 (en) 2025-08-05
MX2021002761A (es) 2021-05-31
CN113056286B (zh) 2025-04-29
CN120267815A (zh) 2025-07-08
JP2022500382A (ja) 2022-01-04
JP7560445B2 (ja) 2024-10-02
WO2020055768A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
Li et al. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite
RU2707882C2 (ru) Нацеленное на gpc3 лекарственное средство, которое вводят пациенту, чувствительному к нацеленной на gpc3 лекарственной терапии
US8486903B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
CN102421919B (zh) 采用Axl作为上皮‑间质转化的生物标志物的方法
JP6081911B2 (ja) Ｓ１００ａ４抗体およびその治療上の使用
US12378320B2 (en) Methods for treating pancreatitis
CN104755496A (zh) 作为癌症治疗和诊断靶标的ly75
JP2011523551A (ja) 血管形成の調節の新規ターゲット
US20200131269A1 (en) Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
AU2016261770B2 (en) Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
JP2017526916A (ja) 癌の診断
US20180318448A1 (en) Method for determining presence or absence of suffering from malignant lymphoma or leukemia, and agent for treatment and/or prevention of leukemia
JP2021531007A (ja) Ｖｉｓｔａに対する受容体
CN111656194B (zh) Tnbc划分和治疗的方法和组合物
RU2839356C2 (ru) Способы лечения панкреатита
US20240174765A1 (en) Anti- enolase 1 (eno1) antibody and applications thereof
CA3151199A1 (en) Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
WO2025217258A1 (en) Nptx1 antibodies
WO2024254596A1 (en) Compositions and methods for detection of aberrant cdk5 expression
Maranda et al. Multiple Intestinal Atresia With Combined Immune Deficiency Related to TTC7A Defect Is a Multiorgan Pathology
WO2019018729A1 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL